Last updated: 11/07/2018 08:33:14
A meta-analysis of three studies to evaluate key efficacy outcomes in subjects with moderate-to-severe Restless Legs Syndrome treated with Gabapentin Enacarbil at doses ranging from 600 mg/day to 2400 mg/day
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A meta-analysis of three studies to evaluate key efficacy outcomes in subjects with moderate-to-severe Restless Legs Syndrome treated with Gabapentin Enacarbil at doses ranging from 600 mg/day to 2400 mg/day
Trial description: The objective of this meta-analysis is to provide supportive evidence of the efficacy of a 600mg dose (the lowest dose evaluated) of GEn in the 12-week placebo controlled studies using the International Restless Legs Scale (IRLS) and the investigator-rated Clinical Global Impression-Improvement (CGI-I) scale, drawing comparisons between GEn and placebo where applicable.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
investigator-rated Clinical Global Impression-Improvement (CGI-I) scale
Timeframe: 12 weeks
International Restless Legs Scale (IRLS)
Timeframe: 12 weeks
Secondary outcomes:
Not applicable
Interventions:
Enrollment:
1
Primary completion date:
Not applicable
Observational study model:
Other
Time perspective:
Retrospective
Clinical publications:
Samantha Warren, Sarah Kavanagh, Susan VanMeter, Ron Barrett. Comparison of Multiple Doses of Gabapentin Enacarbil versus Placebo in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome: An Integrated Analysis of Three 12-Week Studies. [CNS Drugs]. 2012;26(9):773-780.
Medical condition
Restless Legs Syndrome
Product
gabapentin enacarbil
Collaborators
Not applicable
Study date(s)
September 2010 to September 2010
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
none
- All subjects who were randomized into studies XP052, XP053 and XP081
- none
Inclusion and exclusion criteria
Inclusion criteria:
- All subjects who were randomized into studies XP052, XP053 and XP081
Exclusion criteria:
- none
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2010-30-09
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website